Results 121 to 130 of about 210,319 (212)

PRM36 NONPARAMETRIC ESTIMATION OF INCREMENTAL COST EFFECTIVENESS RATIO ACCOUNTING FOR SKEWNESS [PDF]

Value in Health, 2011
openaire   +1 more source

Cost-utility analysis of the Circle of Security-Parenting programme to reduce perinatal psychopathology in birthing parents in England. [PDF]

BMJ Open
Wang J, Rosan C, Alyousefi-van Dijk K, Darwin Z, Babalis D, Cornelius V, Waddingham E, Richards L, Pilling S, Fearon P, Fonagy P, Pizzo E.   +11 more
europepmc   +1 more source

Cost-effectiveness analysis of artificial intelligence-assisted risk stratification of indeterminate pulmonary nodules. [PDF]

PLoS One
Godfrey CM, Leech AA, McGann KC, Zhu J, Marmor HN, Pena S, Pickup LC, Maldonado F, Osmundson EC, Dusetzina SB, Grogan EL, Deppen SA.   +11 more
europepmc   +1 more source

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial. [PDF]

RMD Open
Holly T, Kirkesaether Brun M, Jørgensen KK, Goll GL, Sexton J, Gehin JE, Kvien TK, Jahnsen J, Provan SA, Bolstad N, Aas E, Haavardsholm EA, Kristiansen IS, Syversen SW, Hagen G.   +14 more
europepmc   +1 more source

Evaluating the Health Economic Impacts of Baloxavir Marboxil and Oseltamivir for the Treatment of Influenza in Adult Outpatients in Hong Kong: A Cost-Effectiveness Analysis. [PDF]

Influenza Other Respir Viruses
Chen R, Shao Z, Bi K, Cowling BJ, Du Z.
europepmc   +1 more source

Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma. [PDF]

Cost Eff Resour Alloc
Wang IT, Chen HL, Huang WM, Chiang NJ, Shen LJ, Chueh CH, Tsai YW.   +6 more
europepmc   +1 more source

Cost-effectiveness of sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer in China. [PDF]

PLoS One
Kang S, Yang S, Jia Y, Zhao S.
europepmc   +1 more source

Cost-effectiveness of different strategies with biologics for the treatment of moderate to severe Crohn's disease in China. [PDF]

World J Gastroenterol
Wu Y, Tao LB, Liu C, Wang FX, Yan Y, Sun S.   +5 more
europepmc   +1 more source

Cost effectiveness analysis of immunotherapy regimens currently approved in advanced or recurrent endometrial cancer: An analysis of the NRG-GY 018, RUBY, and DUO-E trials. [PDF]

Gynecol Oncol Rep
Francoeur AA, Liang SY, File B, Choi E, Brameld M, Richardson MT, Johnson CR, Kapp DS, Tewari KS, Chan JK.   +9 more
europepmc   +1 more source

The cost-effectiveness of male-partner treatment to prevent recurrence of bacterial vaginosis. [PDF]

Sci Rep
Zhang Y, Bradshaw CS, Masson L, Smith E, Vodstrcil LA, Ong JJ.   +5 more
europepmc   +1 more source